Publication
Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
Rachel N Grisham, Els Van Nieuwenhuysen, Alessandro D Santin, Véronique D'Hondt, Premal H Thaker, Andrew R Clamp, Kathleen N Moore, Carol Aghajanian, Ana Oaknin, David M O'Malley, Bradley J Monk, Nicoletta Colombo, Emily N Prendergast, Kari L Ring, Isabelle Ray-Coquard, Peter G Rose, Charlie Gourley, Robert W Holloway, Hye Sook Chon, Toon Van Gorp, Hagop Youssoufian, Erin Salinas, Stephanie Lustgarten, Susana N Banerjee
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
OBJECTIVE: In a phase 2 study, avutometinib (RAF/MEK clamp) and defactinib (FAK inhibitor) demonstrated efficacy in patients with recurrent low-grade serous ovarian cancer (LGSOC). Here, we report updated safety and efficacy data with 2 years of follow-up. METHODS: Patients with recurrent LGSOC…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Ovarian Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available